Covid-19 Therapeutic Prospects: Cardiotoxicity Concerns

Abstract

• Page 1 of 2 • Adeyemi. Int J Clin Cardiol 2020, 7:180 Citation: Adeyemi O (2020) Covid-19 Therapeutic Prospects: Cardiotoxicity Concerns. Int J Clin Cardiol 7:180. doi.org/10.23937/2378-2951/1410180 Received: May 08, 2020: Accepted: June 01, 2020; Published: June 03, 2020 Copyright: © 2020 Adeyemi O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. quinacrine after World War I and ultimately produced chloroquine (CQ) in 1934 [6]. Recognition of the value of chloroquine was delayed, and it was not brought forward until it was reevaluated in the United States and designated the drug of choice against malaria near the end of World War II [7]. Chinese experts recommend that mild, moderate and severe COVID-19 cases (without contraindications to CQ) be treated with 500 milligrams of CQ twice daily for 10 days [8]. Years of safety data show that hydroxychloroquine can cause cardiac ECG QT prolongation and subsequent arrhythmias, including torsades de pointes and can prolong the QT correction (QTc), even when taken as recommended [9].